KLOW

KLOW is a four-component research blend supplied in a single lyophilized vial: 50MG GHK-Cu, 10MG BPC-157, 10MG TB-500 and 10MG KPV, 80MG in total. Each component has its own published literature, mostly from cell culture and rodent models. No published study has examined the four together, so this guide summarizes what has been reported for each component, states the study model for every finding, and links to the full guide for each one.

GHK-Cu

GHK binds copper(II), and a 1980 study found that it increased copper uptake into cultured hepatoma cells (Pickart et al., 1980). In fibroblast culture the copper complex stimulated collagen synthesis at picomolar to nanomolar concentrations (Maquart et al., 1988), and in rats fitted with implanted wound chambers it increased collagen, glycosaminoglycan, DNA and total protein accumulation (Maquart et al., 1993).

Structural work describes the complex as monomeric in solution, with copper held by the N-terminal amine, a backbone amide nitrogen and the histidine ring (Hureau et al., 2011). The GHK-Cu research guide also covers the gene-expression, inflammation and formulation studies.

BPC-157

Most BPC-157 work comes from the group that first described it, and it is overwhelmingly preclinical. In rat gastric mucosa the peptide was studied alongside agents that block or supply nitric oxide (Sikirić et al., 1997), and a four-week rat model of short bowel syndrome tracked body weight, villus height and anastomosis strength in BPC-157 groups (Sever et al., 2009).

A separate group reported increased outgrowth from rat tendon explants and higher fibroblast survival and migration, with activation of the FAK-paxillin pathway (Chang et al., 2011). The BPC-157 research guide has the full picture.

TB-500 and thymosin beta-4

Analytical work on material sold as TB-500 identified the acetylated 17 to 23 fragment of thymosin beta-4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, and confirmed it by independent synthesis (Esposito et al., 2012). A doping-control method study described the same fragment as a synthetic version of an active region of the parent protein (Ho et al., 2012).

Most biological data concern the full 43-residue protein: in a rat full-thickness wound model thymosin beta-4 increased re-epithelialization and collagen deposition and stimulated keratinocyte migration in culture (Malinda et al., 1999), and in cardiac cells it formed a complex with PINCH and integrin-linked kinase that activates Akt, with ILK and Akt activity raised in the mouse heart after coronary ligation (Bock-Marquette et al., 2004). Results for the full protein should not be assumed to carry over to the fragment. The BPC-157 vs TB-500 comparison sets the two side by side.

KPV

KPV is the C-terminal tripeptide of alpha-MSH. In human keratinocytes it did not raise cyclic AMP, and it produced rapid intracellular calcium transients when the cyclic AMP pathway was inhibited by an adenosine agonist (Elliott et al., 2004).

In human intestinal epithelial and T cell lines, nanomolar KPV reduced NF-kappaB and MAP kinase signaling, its uptake ran through the PepT1 transporter, and oral administration reduced the severity of two chemically induced colitis models in mice (Dalmasso et al., 2008). Follow-up mouse work linked colitis-associated tumor formation to PepT1 expression and reported that KPV reduced it in wild-type but not PepT1-deficient animals (Viennois et al., 2016). The KPV research guide covers the rest of its literature.

No published study has tested GHK-Cu, BPC-157, TB-500 and KPV together, in any model. There are no data on how the four interact, on the stability of the combined material in solution, or on any combined effect. The nearest published experiment paired two of the components: in a rat Achilles repair model, a BPC-157 plus TB-500 group showed no additive biomechanical effect over TB-500 alone at four weeks (Biçer et al., 2026). Studies using KLOW should handle it as a defined mixture and include controls for each component.